The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis

HIGHLIGHTS

• What: The authors aim to evaluate the presence and severity of to in relation to demographic and MS clinical variables immune profiling and a marker of neuroaxonal damage (plasma light chain (pNfl)). The wearing-off questionnaire was previously developed and validated , and, for this study, was translated in Italian (preliminary iterations were evaluated for the ease of comprehension by five patients). Considering ocrelizumab mechanism of action (anti-CD20 B lymphocytes monoclonal antibody), first, the authors focused on CD19 and CD20 B lymphocytes, but failed to find any significant association, as in Killestein and colleagues , with very low . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.